데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
91449-79-5CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1OHTTJABKRGRZYRN-UHFFFAOYSA-Nenoxaparin fragment has been reported in Hydropuntia edulis, Sargassum myriocystum, and other organisms with data available.
91449-79-5안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
As an anticoagulant, the main risk of LMWH is bleeding. Less common adverse effects include heparin-induced thrombocytopenia, osteoporosis, spontaneous fractures, hypoaldosteronism, and hypersensitivity reactions. In assessing the need for anticoagulant medication, clinicians must consider the risks posed by bleeding versus the risks of clotting.
개요Enoxaparin is a low molecular weight heparin fraction obtained by controlled depolymerization of pig heparin. As an anticoagulant it is reportedly useful in the treatment of venous thromboembolism, and the prevention of coagulation in the extracorporeal circulation during hemodialysis.